DOCSLIB.ORG

6589.Full.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
6589.Full.Pdf Superantigen-Induced Steroid Resistance Depends on Activation of Phospholipase C β2 Auke P. Verhaar, Manon E. Wildenberg, Marjolijn Duijvestein, Anne Christine W. Vos, Maikel P. This information is current as Peppelenbosch, Mark Löwenberg, Daniel W. Hommes and of September 26, 2021. Gijs R. van den Brink J Immunol 2013; 190:6589-6595; Prepublished online 20 May 2013; doi: 10.4049/jimmunol.1202898 Downloaded from http://www.jimmunol.org/content/190/12/6589 References This article cites 17 articles, 6 of which you can access for free at: http://www.jimmunol.org/content/190/12/6589.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 26, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Superantigen-Induced Steroid Resistance Depends on Activation of Phospholipase Cb2 Auke P. Verhaar,*,† Manon E. Wildenberg,† Marjolijn Duijvestein,† Anne Christine W. Vos,* Maikel P. Peppelenbosch,‡ Mark Lo¨wenberg,† Daniel W. Hommes,*,x and Gijs R. van den Brink† The glucocorticoid receptor is present in a TCR-associated complex, which includes the Src family tyrosine kinase Lck. Gluco- corticoids rapidly dissociate this complex, resulting in the inhibition of canonical Lck-phospholipase C (PLC)g–dependent TCR signaling. The relative importance of this nongenomic role for the glucocorticoid receptor compared with its direct transcriptional effects is not known. Superantigens induce a state of steroid resistance in activated T cells. It was reported that, in addition to canonical Lck-PLCg signaling, superantigens can activate a noncanonical G protein–PLCb–dependent signaling pathway. In this study, we show that staphylococcal enterotoxin B activates a Gaq and PLCb2–dependent pathway in human T cells. We find that Downloaded from this pathway bypasses the need for canonical Lck-PLCg signaling in T cell activation and renders superantigen-stimulated T cells insensitive to glucocorticoids in vitro. We show that the PLCb inhibitor U-73122 sensitizes staphylococcal enterotoxin B–treated mice to dexamethasone in vivo. In conclusion, we find that effects of glucocorticoids on TCR-induced T cell proliferation are mainly nongenomic and can be bypassed by the activation of an Lck-independent signaling pathway. The Journal of Immunol- ogy, 2013, 190: 6589–6595. http://www.jimmunol.org/ lucocorticoids bind the glucocorticoid receptor (GR), TCR-associated GR and the resulting inactivation of Lck versus which subsequently dimerizes and translocates from the transcriptionally mediated effects of the GR is not known. If G cytosol to the nucleus. The GR can bind to specific DNA the dissociation and inactivation of Lck are an important part of sequences and alter the transcriptional activity of a wide range of the mechanism of action of steroids, this predicts that signals genes, many of which play a role in the immune system. However, that bypass Lck render T cells relatively insensitive to steroids. the GR also can affect cell signaling in its DNA-unbound state Superantigens activate T cells by directly cross-linking MHC (so-called “nongenomic” or “nontranscriptional effects”) (1). We class II to the TCR as unprocessed proteins. Therefore, super- found previously that the GR is present in a TCR-associated antigens bypass the specificity of conventional Ag recognition and by guest on September 26, 2021 complex that contains the Src-like tyrosine kinase Lck (2). Glu- can activate up to 20% of the total number of T cells (5). The cocorticoids rapidly dissociate the GR from this complex, leading massive activation of the adaptive immune system that ensues to the inactivation of Lck and downstream signaling pathways (2, helps the pathogen to evade an appropriate immune response. The 3). Lck mediates canonical TCR signaling via activation of ZAP- release of cytokines, such as IL-1, TNF-a, and IFN-g, causes the 70, phosphorylation of LAT, and the assembly of a multiprotein signs and symptoms of toxic shock syndrome (TSS) (6). Super- complex. A key component of this complex is phospholipase C antigen signaling is an excellent model to address the question of (PLC)g, which converts phosphatidylinositol 4,5-bisphosphate to the relevance of glucocorticoid-mediated inhibition of upstream inositol 3,4,5-triphosphate and diacylglycerol. Generation of ino- T cell signaling. Superantigens were reported to cause steroid sitol 3,4,5-triphosphate activates Ca2+ signaling and leads to the resistance in T cells (7). More importantly, it was shown that nuclear translocation of NFAT, whereas diacylglycerol activates superantigens can activate a noncanonical G protein–PLCb sig- PKC and RAS-MAPK signaling (see Fig. 1A) (4). Glucocorticoids naling pathway in addition to canonical Lck-PLCg signaling (8). inhibit T cell activation, but the functional relevance of loss of If steroid-mediated inhibition of T cell proliferation depends mainly on nongenomic inhibition of canonical T cell signaling, this pre- dicts that superantigen-mediated glucocorticoid resistance depends *Department of Gastroenterology and Hepatology, Leiden University Medical † on PLCb signaling. Center, 2300RC Leiden, The Netherlands; Department of Gastroenterology and Hepatology, Tytgat Institute for Liver and Intestinal Research, Academic Medical In this study, we find that superantigen-mediated steroid re- Center, 1105AZ Amsterdam, The Netherlands; ‡Department of Gastroenterology and sistance depends on Gaq-mediated activation of PLCb2, which Hepatology, Erasmus Medical Center, 3015CA Rotterdam, The Netherlands; and xCenter for Inflammatory Bowel Diseases, University of California Los Angeles, bypasses dependence on Lck-PLCg signalinginprimaryhuman Los Angeles, CA 90095 T cells in vitro. We go on to show the efficacy of glucocorticoid Received for publication October 18, 2012. Accepted for publication April 16, 2013. therapy in combination with a PLCb inhibitor in a mouse model of This work was supported by an unrestricted research grant from Giuliani Pharma TSS in vivo. These findings have implications for our understanding (Milan, Italy). of the mechanism of action of glucocorticoids. They may point to Address correspondence and reprint requests to Dr. Gijs R. Van den Brink, Academic novel therapeutic strategies to counter glucocorticoid resistance. Medical Center, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands. E-mail address: [email protected] Abbreviations used in this article: GR, glucocorticoid receptor; PBL, peripheral Materials and Methods blood leukocyte; PLC, phospholipase C; RT, room temperature; SEB, staphylococcal Abs and reagents enterotoxin B; siRNA, small interfering RNA; TSS, toxic shock syndrome. The following Abs were purchased from Santa Cruz Biotechnology Copyright Ó 2013 by The American Association of Immunologists, Inc. 0022-1767/13/$16.00 (Heidelberg, Germany): anti-Lck (3A5), anti–b-actin, anti-PLCb1 (D-8), www.jimmunol.org/cgi/doi/10.4049/jimmunol.1202898 6590 SUPERANTIGEN-INDUCED STEROID RESISTANCE anti-PLCb2 (Q-15), anti-PLCb3 (C-20), and anti-pTyr (PY20). Anti– Small interfering RNA transfection phospho-Zap70 (Tyr319)/Syk (Tyr352), anti–phospho-Src (Tyr410), anti– phospho-LAT (Tyr171), and the PI3K inhibitor LY924002 were purchased Two independent small interfering RNAs (siRNAs) targeting GNA11 from Cell Signaling Technology (Beverly, MA). Anti-PLCg1 (2B1) was (siRNA #1: CGACAAGAUCAUCUACUCAtt, siRNA #2: GCAUCAUC- purchased from Abcam (Cambridge, MA). Anti-CD3 and anti-CD28 were GAGUACCCUUUtt), GNAq (siRNA #1: UCGUCUAUCAUAGCAUUC- purchased from Sanquin (Amsterdam, The Netherlands). PMA, ionomycin, Ctg, siRNA #2: UAUCUUCAUCAGAGUAUCCtg), and PLCb2 (siRNA staphylococcal enterotoxin B (SEB), and the PLCb inhibitor U-73122 were #1: GGCUACUACUUAUACUGGAtt, siRNA #2: CCAUGACCACAGA- purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). PHA-M CAUCUUtt) were purchased from Ambion Applied Biosystems (Austin, was purchased from Roche (Mannheim, Germany). TX). Lymphocytes were transfected by electroporation using Amaxa’s Nucleofector (Lonza, Cologne, Germany). 6 Mice A total of 10 3 10 lymphocytes was electroporated per condition, accordingtoprotocol,using30pmolsiRNAandtheHumanTCell Eight-week-old female C57BL/6 wild-type mice were purchased from Nucleofector Kit for unstimulated T cells (Lonza, Cologne, Germany). Harlan (Boxmeer, The Netherlands) and housed in pathogen-free con- The media were replaced after 4 h. Experiments were performed 48 h ditions. All mice received a single i.p. injection with a total volume of posttransfection. 500 ml. Depending on the group, mice received 20 mg dexamethasone and/or 10 mg U-73122. All mice received 8.8 ml DMSO, 100 mgSEB. Quantification and data analysis Twenty-four hours later, the mice were euthanatized with
Load more

Recommended publications
  • Silencing of Phosphoinositide-Specific
    ANTICANCER RESEARCH 34: 4069-4076 (2014) Silencing of Phosphoinositide-specific Phospholipase C ε Remodulates the Expression of the Phosphoinositide Signal Transduction Pathway in Human Osteosarcoma Cell Lines VINCENZA RITA LO VASCO1, MARTINA LEOPIZZI2, DANIELA STOPPOLONI3 and CARLO DELLA ROCCA2 Departments of 1Sense Organs , 2Medicine and Surgery Sciences and Biotechnologies and 3Biochemistry Sciences “A. Rossi Fanelli”, Sapienza University, Rome, Italy Abstract. Background: Ezrin, a member of the signal transduction pathway (5). The reduction of PIP2 ezrin–radixin–moesin family, is involved in the metastatic induces ezrin dissociation from the plasma membrane (6). spread of osteosarcoma. Ezrin binds phosphatydil inositol-4,5- The levels of PIP2 are regulated by the PI-specific bisphosphate (PIP2), a crucial molecule of the phospholipase C (PI-PLC) family (7), constituting thirteen phosphoinositide signal transduction pathway. PIP2 levels are enzymes divided into six sub-families on the basis of amino regulated by phosphoinositide-specific phospholipase C (PI- acid sequence, domain structure, mechanism of recruitment PLC) enzymes. PI-PLCε isoform, a well-characterized direct and tissue distribution (7-15). PI-PLCε, a direct effector of effector of rat sarcoma (RAS), is at a unique convergence RAS (14-15), might be the point of convergence for the point for the broad range of signaling pathways that promote broad range of signalling pathways that promote the RAS GTPase-mediated signalling. Materials and Methods. By RASGTPase-mediated signalling (16). using molecular biology methods and microscopic analyses, In previous studies, we suggested a relationship between we analyzed the expression of ezrin and PLC genes after PI-PLC expression and ezrin (17-18).
    [Show full text]
  • Survival-Associated Metabolic Genes in Colon and Rectal Cancers
    Survival-associated Metabolic Genes in Colon and Rectal Cancers Yanfen Cui ( [email protected] ) Tianjin Cancer Institute: Tianjin Tumor Hospital https://orcid.org/0000-0001-7760-7503 Baoai Han tianjin tumor hospital He Zhang tianjin tumor hospital Zhiyong Wang tianjin tumor hospital Hui Liu tianjin tumor hospital Fei Zhang tianjin tumor hospital Ruifang Niu tianjin tumor hospital Research Keywords: colon cancer, rectal cancer, prognosis, metabolism Posted Date: December 4th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-117478/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/42 Abstract Background Uncontrolled proliferation is the most prominent biological feature of tumors. To rapidly proliferate and maximize the use of available nutrients, tumor cells regulate their metabolic behavior and the expression of metabolism-related genes (MRGs). In this study, we aimed to construct prognosis models for colon and rectal cancers, using MRGs to indicate the prognoses of patients. Methods We rst acquired the gene expression proles of colon and rectal cancers from the TCGA and GEO database, and utilized univariate Cox analysis, lasso regression, and multivariable cox analysis to identify MRGs for risk models. Then GSEA and KEGG functional enrichment analysis were utilized to identify the metabolism pathway of MRGs in the risk models and analyzed these genes comprehensively using GSCALite. Results Eight genes (CPT1C, PLCB2, PLA2G2D, GAMT, ENPP2, PIP4K2B, GPX3, and GSR) in the colon cancer risk model and six genes (TDO2, PKLR, GAMT, EARS2, ACO1, and WAS) in the rectal cancer risk model were identied successfully. Multivariate Cox analysis indicated that the models predicted overall survival accurately and independently for patients with colon or rectal cancer.
    [Show full text]
  • Effective Angiogenesis Requires Regulation of Phosphoinositide Signaling
    Effective angiogenesis requires regulation of phosphoinositide signaling Elizabeth Michele Davies, Rajendra Gurung, Kai Qin Le, Christina Anne Mitchell* Cancer Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Victoria 3800, Australia *Corresponding author [email protected] Abstract Phosphoinositide signaling regulates numerous downstream effectors that mediate cellular processes which influence cell cycle progression, migration, proliferation, growth, survival, metabolism and vesicular trafficking. A prominent role for phosphoinositide 3-kinase, which generates phosphatidylinositol 3,4,5-trisphosphate, a phospholipid that activates a plethora of effectors including AKT and FOXO during embryonic and postnatal angiogenesis, has been described. In addition, phosphatidylinositol 3-phosphate signaling is required for endosomal trafficking, which contributes to vascular remodeling. This review will examine the role phosphoinositide signaling plays in the endothelium and its contribution to sprouting angiogenesis. Keywords Angiogenesis, Phosphoinositide, PI3K, PTEN 1. Introduction Establishment of a functional vasculature is essential for embryonic development, and also for the maintenance of tissue regeneration, inflammatory responses and wound healing in the adult. Vascular development is characterized by two distinct physiological processes, vasculogenesis and angiogenesis. Vasculogenesis is predominantly limited to embryonic development, whereby differentiation
    [Show full text]
  • Supplementary Table 1 List of 335 Genes Differentially Expressed Between Primary (P) and Metastatic (M) Tumours
    Supplementary Table 1 List of 335 genes differentially expressed between primary (P) and metastatic (M) tumours Spot ID I.M.A.G.E. UniGene Symbol Name Clone ID Cluster 296529 296529 In multiple clusters 731356 731356 Hs.140452 M6PRBP1 mannose-6-phosphate receptor binding protein 1 840942 840942 Hs.368409 HLA-DPB1 major histocompatibility complex, class II, DP beta 1 142122 142122 Hs.115912 AFAP actin filament associated protein 1891918 1891918 Hs.90073 CSE1L CSE1 chromosome segregation 1-like (yeast) 1323432 1323432 Hs.303154 IDS iduronate 2-sulfatase (Hunter syndrome) 788566 788566 Hs.80296 PCP4 Purkinje cell protein 4 591281 591281 Hs.80680 MVP major vault protein 815530 815530 Hs.172813 ARHGEF7 Rho guanine nucleotide exchange factor (GEF) 7 825312 825312 Hs.246310 ATP5J ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F6 784830 784830 Hs.412842 C10orf7 chromosome 10 open reading frame 7 840878 840878 Hs.75616 DHCR24 24-dehydrocholesterol reductase 669443 669443 Hs.158195 HSF2 heat shock transcription factor 2 2485436 2485436 Data not found 82903 82903 Hs.370937 TAPBP TAP binding protein (tapasin) 771258 771258 Hs.85258 CD8A CD8 antigen, alpha polypeptide (p32) 85128 85128 Hs.8986 C1QB complement component 1, q subcomponent, beta polypeptide 41929 41929 Hs.39252 PICALM phosphatidylinositol binding clathrin assembly protein 148469 148469 Hs.9963 TYROBP TYRO protein tyrosine kinase binding protein 415145 415145 Hs.1376 HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 810017 810017 Hs.179657 PLAUR plasminogen activator,
    [Show full text]
  • Supplementary Table S2
    1-high in cerebrotropic Gene P-value patients Definition BCHE 2.00E-04 1 Butyrylcholinesterase PLCB2 2.00E-04 -1 Phospholipase C, beta 2 SF3B1 2.00E-04 -1 Splicing factor 3b, subunit 1 BCHE 0.00022 1 Butyrylcholinesterase ZNF721 0.00028 -1 Zinc finger protein 721 GNAI1 0.00044 1 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 GNAI1 0.00049 1 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 PDE1B 0.00069 -1 Phosphodiesterase 1B, calmodulin-dependent MCOLN2 0.00085 -1 Mucolipin 2 PGCP 0.00116 1 Plasma glutamate carboxypeptidase TMX4 0.00116 1 Thioredoxin-related transmembrane protein 4 C10orf11 0.00142 1 Chromosome 10 open reading frame 11 TRIM14 0.00156 -1 Tripartite motif-containing 14 APOBEC3D 0.00173 -1 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D ANXA6 0.00185 -1 Annexin A6 NOS3 0.00209 -1 Nitric oxide synthase 3 SELI 0.00209 -1 Selenoprotein I NYNRIN 0.0023 -1 NYN domain and retroviral integrase containing ANKFY1 0.00253 -1 Ankyrin repeat and FYVE domain containing 1 APOBEC3F 0.00278 -1 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F EBI2 0.00278 -1 Epstein-Barr virus induced gene 2 ETHE1 0.00278 1 Ethylmalonic encephalopathy 1 PDE7A 0.00278 -1 Phosphodiesterase 7A HLA-DOA 0.00305 -1 Major histocompatibility complex, class II, DO alpha SOX13 0.00305 1 SRY (sex determining region Y)-box 13 ABHD2 3.34E-03 1 Abhydrolase domain containing 2 MOCS2 0.00334 1 Molybdenum cofactor synthesis 2 TTLL6 0.00365 -1 Tubulin tyrosine ligase-like family, member 6 SHANK3 0.00394 -1 SH3 and multiple ankyrin repeat domains 3 ADCY4 0.004 -1 Adenylate cyclase 4 CD3D 0.004 -1 CD3d molecule, delta (CD3-TCR complex) (CD3D), transcript variant 1, mRNA.
    [Show full text]
  • 140503 IPF Signatures Supplement Withfigs Thorax
    Supplementary material for Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis Daryle J. DePianto1*, Sanjay Chandriani1⌘*, Alexander R. Abbas1, Guiquan Jia1, Elsa N. N’Diaye1, Patrick Caplazi1, Steven E. Kauder1, Sabyasachi Biswas1, Satyajit K. Karnik1#, Connie Ha1, Zora Modrusan1, Michael A. Matthay2, Jasleen Kukreja3, Harold R. Collard2, Jackson G. Egen1, Paul J. Wolters2§, and Joseph R. Arron1§ 1Genentech Research and Early Development, South San Francisco, CA 2Department of Medicine, University of California, San Francisco, CA 3Department of Surgery, University of California, San Francisco, CA ⌘Current address: Novartis Institutes for Biomedical Research, Emeryville, CA. #Current address: Gilead Sciences, Foster City, CA. *DJD and SC contributed equally to this manuscript §PJW and JRA co-directed this project Address correspondence to Paul J. Wolters, MD University of California, San Francisco Department of Medicine Box 0111 San Francisco, CA 94143-0111 [email protected] or Joseph R. Arron, MD, PhD Genentech, Inc. MS 231C 1 DNA Way South San Francisco, CA 94080 [email protected] 1 METHODS Human lung tissue samples Tissues were obtained at UCSF from clinical samples from IPF patients at the time of biopsy or lung transplantation. All patients were seen at UCSF and the diagnosis of IPF was established through multidisciplinary review of clinical, radiological, and pathological data according to criteria established by the consensus classification of the American Thoracic Society (ATS) and European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and the Latin American Thoracic Association (ALAT) (ref. 5 in main text). Non-diseased normal lung tissues were procured from lungs not used by the Northern California Transplant Donor Network.
    [Show full text]
  • Supp Table 6.Pdf
    Supplementary Table 6. Processes associated to the 2037 SCL candidate target genes ID Symbol Entrez Gene Name Process NM_178114 AMIGO2 adhesion molecule with Ig-like domain 2 adhesion NM_033474 ARVCF armadillo repeat gene deletes in velocardiofacial syndrome adhesion NM_027060 BTBD9 BTB (POZ) domain containing 9 adhesion NM_001039149 CD226 CD226 molecule adhesion NM_010581 CD47 CD47 molecule adhesion NM_023370 CDH23 cadherin-like 23 adhesion NM_207298 CERCAM cerebral endothelial cell adhesion molecule adhesion NM_021719 CLDN15 claudin 15 adhesion NM_009902 CLDN3 claudin 3 adhesion NM_008779 CNTN3 contactin 3 (plasmacytoma associated) adhesion NM_015734 COL5A1 collagen, type V, alpha 1 adhesion NM_007803 CTTN cortactin adhesion NM_009142 CX3CL1 chemokine (C-X3-C motif) ligand 1 adhesion NM_031174 DSCAM Down syndrome cell adhesion molecule adhesion NM_145158 EMILIN2 elastin microfibril interfacer 2 adhesion NM_001081286 FAT1 FAT tumor suppressor homolog 1 (Drosophila) adhesion NM_001080814 FAT3 FAT tumor suppressor homolog 3 (Drosophila) adhesion NM_153795 FERMT3 fermitin family homolog 3 (Drosophila) adhesion NM_010494 ICAM2 intercellular adhesion molecule 2 adhesion NM_023892 ICAM4 (includes EG:3386) intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)adhesion NM_001001979 MEGF10 multiple EGF-like-domains 10 adhesion NM_172522 MEGF11 multiple EGF-like-domains 11 adhesion NM_010739 MUC13 mucin 13, cell surface associated adhesion NM_013610 NINJ1 ninjurin 1 adhesion NM_016718 NINJ2 ninjurin 2 adhesion NM_172932 NLGN3 neuroligin
    [Show full text]
  • Chemical Agent and Antibodies B-Raf Inhibitor RAF265
    Supplemental Materials and Methods: Chemical agent and antibodies B-Raf inhibitor RAF265 [5-(2-(5-(trifluromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-trifluoromethyl)phenyl-1-methyl-1H-benzp{D, }imidazol-2- amine] was kindly provided by Novartis Pharma AG and dissolved in solvent ethanol:propylene glycol:2.5% tween-80 (percentage 6:23:71) for oral delivery to mice by gavage. Antibodies to phospho-ERK1/2 Thr202/Tyr204(4370), phosphoMEK1/2(2338 and 9121)), phospho-cyclin D1(3300), cyclin D1 (2978), PLK1 (4513) BIM (2933), BAX (2772), BCL2 (2876) were from Cell Signaling Technology. Additional antibodies for phospho-ERK1,2 detection for western blot were from Promega (V803A), and Santa Cruz (E-Y, SC7383). Total ERK antibody for western blot analysis was K-23 from Santa Cruz (SC-94). Ki67 antibody (ab833) was from ABCAM, Mcl1 antibody (559027) was from BD Biosciences, Factor VIII antibody was from Dako (A082), CD31 antibody was from Dianova, (DIA310), and Cot antibody was from Santa Cruz Biotechnology (sc-373677). For the cyclin D1 second antibody staining was with an Alexa Fluor 568 donkey anti-rabbit IgG (Invitrogen, A10042) (1:200 dilution). The pMEK1 fluorescence was developed using the Alexa Fluor 488 chicken anti-rabbit IgG second antibody (1:200 dilution).TUNEL staining kits were from Promega (G2350). Mouse Implant Studies: Biopsy tissues were delivered to research laboratory in ice-cold Dulbecco's Modified Eagle Medium (DMEM) buffer solution. As the tissue mass available from each biopsy was limited, we first passaged the biopsy tissue in Balb/c nu/Foxn1 athymic nude mice (6-8 weeks of age and weighing 22-25g, purchased from Harlan Sprague Dawley, USA) to increase the volume of tumor for further implantation.
    [Show full text]
  • Strand Breaks for P53 Exon 6 and 8 Among Different Time Course of Folate Depletion Or Repletion in the Rectosigmoid Mucosa
    SUPPLEMENTAL FIGURE COLON p53 EXONIC STRAND BREAKS DURING FOLATE DEPLETION-REPLETION INTERVENTION Supplemental Figure Legend Strand breaks for p53 exon 6 and 8 among different time course of folate depletion or repletion in the rectosigmoid mucosa. The input of DNA was controlled by GAPDH. The data is shown as ΔCt after normalized to GAPDH. The higher ΔCt the more strand breaks. The P value is shown in the figure. SUPPLEMENT S1 Genes that were significantly UPREGULATED after folate intervention (by unadjusted paired t-test), list is sorted by P value Gene Symbol Nucleotide P VALUE Description OLFM4 NM_006418 0.0000 Homo sapiens differentially expressed in hematopoietic lineages (GW112) mRNA. FMR1NB NM_152578 0.0000 Homo sapiens hypothetical protein FLJ25736 (FLJ25736) mRNA. IFI6 NM_002038 0.0001 Homo sapiens interferon alpha-inducible protein (clone IFI-6-16) (G1P3) transcript variant 1 mRNA. Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 15 GALNTL5 NM_145292 0.0001 (GALNT15) mRNA. STIM2 NM_020860 0.0001 Homo sapiens stromal interaction molecule 2 (STIM2) mRNA. ZNF645 NM_152577 0.0002 Homo sapiens hypothetical protein FLJ25735 (FLJ25735) mRNA. ATP12A NM_001676 0.0002 Homo sapiens ATPase H+/K+ transporting nongastric alpha polypeptide (ATP12A) mRNA. U1SNRNPBP NM_007020 0.0003 Homo sapiens U1-snRNP binding protein homolog (U1SNRNPBP) transcript variant 1 mRNA. RNF125 NM_017831 0.0004 Homo sapiens ring finger protein 125 (RNF125) mRNA. FMNL1 NM_005892 0.0004 Homo sapiens formin-like (FMNL) mRNA. ISG15 NM_005101 0.0005 Homo sapiens interferon alpha-inducible protein (clone IFI-15K) (G1P2) mRNA. SLC6A14 NM_007231 0.0005 Homo sapiens solute carrier family 6 (neurotransmitter transporter) member 14 (SLC6A14) mRNA.
    [Show full text]
  • Changes in Gene Expression Under MET-Stress in CAPAN1 and CFPAC1
    Supplement: Changes in gene expression under MET-stress in CAPAN1 and CFPAC1. Significant (<0.05) changes of 2.5 fold or greater that occur in cultures under MET-stress for either CAPAN1 or CFPAC for 4 and 6 d respectively, are listed. NE: not expressed denotes relative expression of less than 200 in both methionine (M) and homocysteine (H) sets. CAPAN1 CAPAN1 CFPAC1 CFPAC1 GENE SYMBOL CHROMOSOME MET HCYS M/H MET HCYS M/H Growth arrest and DNA-damage-inducible, beta GADD45B chr19p13.3 47.4 2605.4 0.02 546.5 978.9 0.56 clusterin CLU chr8p21-p12 31 610.2 0.05 NE cyclin-dependent kinase 5 CDK5 chr7q36 44 502.3 0.09 286.1 628.4 0.46 SMAD, mothers against DPP homolog 7 SMAD7 chr18q21.1 30.1 337.2 0.09 410.8 968.3 0.63 colony stimulating factor 1 (macrophage) CSF1 chr1p21-p13 50.4 487.1 0.10 1105.5 1741.8 0.42 breast cancer 1, early onset BRCA1 chr17q21 31.6 316.5 0.11 125.5 427.1 0.29 TGF, beta receptor associated protein 1 TGFBRAP1 chr2q12.1 72.9 648.9 0.11 NE tuftelin interacting protein 11 TFIP11 chr22q12.1 63.8 561.5 0.11 212.2 382 0.56 three prime repair exonuclease 1 TREX1 chr3p21.3-p21.2 39.8 310.1 0.13 59.5 310.8 0.19 v-ets erythroblastosis virus E26 oncogene homolog2 ETS2 chr21q22.3|21q22.2 105 807.1 0.13 615.9 414.2 1.49 growth differentiation factor 15 GDF15 chr19p13.1-13.2 275 1940.1 0.14 4961.8 6636.5 0.75 c-myc binding protein MYCBP chr1p33-p32.2 32.4 226.8 0.14 448.6 525.5 0.85 protein (peptidyl-prolyl cis/trans isomerase) 1 PIN1 chr19p13 102 683.8 0.15 NE putative lymphocyte G0/G1 switch gene G0S2 chr1q32.2-q41 1485.3 9136.8
    [Show full text]
  • Potent Lipolytic Activity of Lactoferrin in Mature Adipocytes
    Biosci. Biotechnol. Biochem., 77 (3), 566–571, 2013 Potent Lipolytic Activity of Lactoferrin in Mature Adipocytes y Tomoji ONO,1;2; Chikako FUJISAKI,1 Yasuharu ISHIHARA,1 Keiko IKOMA,1;2 Satoru MORISHITA,1;3 Michiaki MURAKOSHI,1;4 Keikichi SUGIYAMA,1;5 Hisanori KATO,3 Kazuo MIYASHITA,6 Toshihide YOSHIDA,4;7 and Hoyoku NISHINO4;5 1Research and Development Headquarters, Lion Corporation, 100 Tajima, Odawara, Kanagawa 256-0811, Japan 2Department of Supramolecular Biology, Graduate School of Nanobioscience, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan 3Food for Life, Organization for Interdisciplinary Research Projects, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan 4Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyou-ku, Kyoto 602-8566, Japan 5Research Organization of Science and Engineering, Ritsumeikan University, 1-1-1 Nojihigashi, Kusatsu, Shiga 525-8577, Japan 6Department of Marine Bioresources Chemistry, Faculty of Fisheries Sciences, Hokkaido University, 3-1-1 Minatocho, Hakodate, Hokkaido 041-8611, Japan 7Kyoto City Hospital, 1-2 Higashi-takada-cho, Mibu, Nakagyou-ku, Kyoto 604-8845, Japan Received October 22, 2012; Accepted November 26, 2012; Online Publication, March 7, 2013 [doi:10.1271/bbb.120817] Lactoferrin (LF) is a multifunctional glycoprotein resistance, high blood pressure, and dyslipidemia. To found in mammalian milk. We have shown in a previous prevent progression of metabolic syndrome, lifestyle clinical study that enteric-coated bovine LF tablets habits must be improved to achieve a balance between decreased visceral fat accumulation. To address the energy intake and consumption. In addition, the use of underlying mechanism, we conducted in vitro studies specific food factors as helpful supplements is attracting and revealed the anti-adipogenic action of LF in pre- increasing attention.
    [Show full text]
  • Small Molecule Protein–Protein Interaction Inhibitors As CNS Therapeutic Agents: Current Progress and Future Hurdles
    Neuropsychopharmacology REVIEWS (2009) 34, 126–141 & 2009 Nature Publishing Group All rights reserved 0893-133X/09 $30.00 ............................................................................................................................................................... REVIEW 126 www.neuropsychopharmacology.org Small Molecule Protein–Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future Hurdles 1 ,1,2,3 Levi L Blazer and Richard R Neubig* 1Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, USA; 2Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; 3Center for Chemical Genomics, University of Michigan Medical School, Ann Arbor, MI, USA Protein–protein interactions are a crucial element in cellular function. The wealth of information currently available on intracellular-signaling pathways has led many to appreciate the untapped pool of potential drug targets that reside downstream of the commonly targeted receptors. Over the last two decades, there has been significant interest in developing therapeutics and chemical probes that inhibit specific protein–protein interactions. Although it has been a challenge to develop small molecules that are capable of occluding the large, often relatively featureless protein–protein interaction interface, there are increasing numbers of examples of small molecules that function in this manner with reasonable potency. This article will highlight the current progress in the development of small
    [Show full text]